Oncology CME

The New York Medical Cannabis Program Required Course Bundle has been approved by the New York State Office of Cannabis Management and satisfies the New York educational requirements to become a practitioner with the New York Medical Cannabis Program.

This bundle introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses various aspects of medical marijuana, including administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

The New York State Medical Cannabis Program Rules and Regulations are outlined in a state-specific course, as well.

The Ohio Healthcare Provider Medical Marijuana Course Bundle for Certification (or maintenance of the CTR) is certified by the Ohio State Medical Association and satisfies the CME requirements for the initial Ohio Certificate to Recommend (CTR) application or for maintenance of the CTR.

This bundle introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses various aspects of medical marijuana, including administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

The Ohio Medical Marijuana Control Program rules and regulations are outlined in a state-specific course, as well.

The Pennsylvania Medical Marijuana Program Required Course Bundle has been approved by the Pennsylvania Department of Health and satisfies the Pennsylvania educational requirements to become a practitioner with the Pennsylvania Medical Marijuana Program.

This bundle introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses various aspects of medical marijuana, including administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

This course bundle also addresses the use of cannabidiol (CBD) in clinical care, and the information will assist clinicians in effectively treating and counseling CBD consumers. The physiological effects of CBD, CBD drug interactions, CBD’s side effects, and the conditions for which CBD has been shown by evidence-based clinical studies to be efficacious are all discussed in this course bundle.

The Pennsylvania Medical Marijuana Program rules and regulations are outlined in a state-specific course, as well.

The Utah Medical Cannabis Program Required Course Bundle has been approved by the Utah Department of Health and satisfies the Utah educational requirements to become a practitioner with the Utah Medical Cannabis Program.

The Utah Medical Cannabis Program Required Course Bundle introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

This course bundle also provides information that assists clinicians in effectively treating and counseling CBD consumers.

The West Virginia Medical Cannabis Program Required Course Bundle has been approved by the West Virginia Department of Health and Human Resources, Bureau for Public Health, Office of Medical Cannabis and satisfies the West Virginia educational requirements to become a practitioner with the West Virginia Medical Cannabis Program.

This course introduces the reader to the endocannabinoid system and its interaction with the components of the cannabis plant, and addresses administration, therapeutic use, drug metabolism, physiologic and cognitive effects, potential risks, and drug interactions.

The use of marijuana in obstetric patients, pediatric patients, adolescent patients and elderly patients is discussed in detail. Important considerations for patients with ischemic heart disease, hepatic disease, psychotic illness, and those with a history of drug dependence are provided.

This course bundle also addresses the use of cannabidiol (CBD) in clinical care, and the information will assist clinicians in effectively treating and counseling CBD consumers. The physiological effects of CBD, CBD drug interactions, CBD’s side effects, and the conditions for which CBD has been shown by evidence-based clinical studies to be efficacious are all discussed in this course bundle.

The West Virginia medical cannabis program rules and regulations are outlined in a state-specific course, as well.

The West Virginia medical cannabis program rules and regulations are outlined in a state-specific course, as well.

In this online, self-learning activity:

Renal cell carcinoma (RCC) is a cancer that develops in the nephrons. It is responsible for most cancers of the kidney and renal pelvis, which occur in close to 82,000 people and account for over 14,000 deaths in the U.S. annually. The five-year survival rate is 93% for patients with early stages of the disease. However, in patients with advanced or metastatic disease, the five-year survival is 17%, representing an area of ongoing clinical need.

The AudioDigest CME + CE + MOC Anesthesiology Platinum Membership is our most comprehensive plan available. Get unlimited access to every lecture in our library across all specialties, including over 2500 evidence-based audio lessons and written summaries with suggested readings and test questions certified for CME, CE, and MOC credits across 14 specialties.

A new, comprehensive resource designed to support clinicians across all specialties. Whether you’re treating heart disease, infectious illnesses, or managing preventive care, this collection offers a unique blend of pharmacology updates and lifestyle intervention strategies. With topics ranging from pediatric obesity to hyperbilirubinemia in newborns, and from cell therapy to adult and adolescent vaccinations, Clinical Guidelines & Updates Topical Collection equips you with practical insights that can be applied directly to everyday care.

In this online, self-learning activity:

Over 64,000 people develop and close 50,000 die each year of pancreatic cancer, and by 2030, pancreatic cancer is expected to surpass colorectal and breast cancer to become the second-leading cause of cancer death. Over 90% of whom have pancreatic ductal adenocarcinoma (PDAC), and while the 5-year survival rate for patients diagnosed with localized disease is over 44%, patients with locally advanced (LAPC) or metastatic disease have a median overall survival of 12 to 14 months. Symptoms associated with pancreatic cancer are not usually evident in the early stages of the disease and may be intermittent and nonspecific, and more than half of patients have advanced disease by the time they are diagnosed.

The Mid East Chapter of the Society of Nuclear Medicine and Molecular Imaging’s historic 50th Annual Conference presents nuclear medicine’s latest trends, advances and procedures. Adapted for the enduring material audience, Nuclear Medicine and Molecular Imaging Update features a dozen faculty members presenting this specialty’s impact on imaging, cardiology, neurology, endocrinology, oncology, rheumatology, pediatrics and much more. Practice enhancements and professional development will be discussed, as well. Nuclear Medicine and Molecular Imaging Update provides a well rounded refresher for all physicians and technologists involved with this area of medicine.

In this online, self-learning activity:

Multiple myeloma (MM) is the most common hematologic malignancy after non-Hodgkin lymphoma, with an incidence of over 34,000 and an annual mortality rate of over 12,000. MM-induced osteocyte apoptosis facilitates MM cell survival, and patients with MM are at high risk for bone disease. Osteolytic lesions are reported in up to four out of five newly diagnosed with MM, and throughout their disease course, up to 90% of patients will eventually develop bone lesions. The presence of bone lesions increases MM patient risk for skeletal-related events (SREs), such as fractures, spinal cord compression, or need for surgery or radiotherapy. Bone disease and SREs can have serious consequences in MM, leading to worsened quality-of-life and prospects for survival. Patients who experience fracture after MM diagnosis have a two-fold increased risk of death relative to those who do not experience fracture. Yet bone disease frequently goes untreated in patients with MM, suggesting that clinicians are not familiar with the serious effects of MM.

Activity Description / Statement of Need:

In this online, self-learning activity:

Graft-versus-host disease (GvHD) is an immune-mediated response that occurs in recipients of allogenic hematopoietic cell transplantation (HCT). GvHD can be further categorized into acute and chronic cases. Maculopapular rash, follicular erythema, epidermolysis, are common manifestations of acute GvHD, in addition to liver and gastrointestinal dysfunction such as hyperbilirubinemia, nausea, and diarrhea. This activity focuses on chronic GvHD, which has more extensive multi-organ involvement including the liver, eyes, mouth, lungs, skin, genitalia, and gastrointestinal tract.

Target Audience:

The following HCPs: hematologists and oncologists; nurse practitioners, physician assistants, and pharmacists who specialize in oncology; and those who otherwise commonly care for or clinically encounter patients with GVHD.

Activity Description / Statement of Need:
In this online, self-learning activity:

Systemic mastocytosis (SM) is a heterogeneous group of disorders caused by proliferation of abnormal clonal mastocytes, which accumulate in the skin and/or other organ systems. Mastocytosis, including SM, was reclassified as a distinct disease subtype in 2016, when the World Health Organization (WHO) removed mastocytosis from the myeloproliferative neoplasm (MPN) group. The WHO defines 5 SM subtypes, ranging from indolent SM, which is associated with mild symptoms and near-normal life expectancy, to mast cell leukemia, which is an aggressive hematologic malignancy associated with median survival of less than 1 year.

Target Audience:
HCPs including: hematology/oncology specialists, allergists, and clinical immunologists, dermatologists; physician assistants, nurse practitioners, and pharmacists who practice in those areas of specialty; and any other healthcare professionals with an interest in or who may clinically encounter patients with systemic mastocytosis.

Penn Radiology Emergency Imaging After Hours provides insight for imaging conditions where rapid response is required. An elite faculty guides learners with practical lessons in modality choice, image acquisition and interpretation skills for a wide range of clinical presentations. Selected topics in chest, neuroradiology, abdominal, pelvic, pediatric and musculoskeletal imaging are presented to ensure confident analysis, so the practitioner is never outside of their comfort zone. Worth up to 15.75 AMA PRA Category I Credits™, all applicable as SA-CME for Maintenance of Certification requirements.

Each year, more than 290,000 cases of breast cancer are diagnosed, making it the leading cause of cancer among females in the United States. Although earlier screening and more effective treatment options have improved outcomes among people with breast cancer, more than 43,000 people die from this type of cancer each year. Throughout the course of breast cancer management, bone health remains an important consideration. In early breast cancer, chemotherapy-induced ovarian failure and endocrine therapy can contribute to BMD loss and subsequent osteoporosis and fracture. In advanced breast cancer, about 70% of all patients will experience bone metastases, placing patients at risk for SREs. In fact, breast cancer is associated with the highest risk of SREs among all tumor types.

Maintaining bone health in patients with breast cancer requires routine monitoring and proactive management to minimize the risk of BMD loss, osteoporosis, and SREs. Guidelines therefore recommend that patients with non-metastatic breast cancer initiating aromatase inhibitors or other treatment that causes bone loss undergo dual-energy X-ray absorptiometry (DXA) scans to assess baseline BMD. Furthermore, patients at risk for osteoporosis should receive regular follow-up DXA scans to monitor for BMD loss. This represents an opportunity for ongoing education about the need for monitoring to ensure maintenance of optimal bone health.

This video activity focuses on ways to help early detection of breast cancer by learning the risk factors, the different screening and diagnostic modalities and guidelines to what kind of screening is needed, and most importantly, when should screening begin.

From October to December, 2022, 50% of the proceeds from this course will be donated to the National Breast Cancer Foundation. Despite the advances in breast cancer detection and treatment, on the psychological side, clinicians who have been involved in the emotional care of cancer patients can report that a breast cancer diagnosis can nevertheless generate many concerns for patients, as well as their families. Psychological interventions for breast cancer patients have well-documented success in reducing distress and enhancing psychosocial adaptation to disease. As such, these interventions have been highlighted as important mechanisms by which physical health can be improved. This activity focuses on the common issues that impact psychological adjustment to breast cancer and interventions that will help optimize care in the cancer context.

There is a growing prevalence of breast cancer among adolescents and young adults (AYAs) aged 15 to 39 years old, and people of color (POCs). Breast cancer tends to present as more advance and aggressive forms in both of these demographics and is unfortunately associated with higher mortality rates than other populations in whom mortality rates have been decreasing over the last few decades.

This activity highlights the current trends, challenges, and health disparities experienced by AYAs and POCs with breast cancer, and provides insight into possible ways of improving screening and overall management of these patients.